Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Rethymic® (allogeneic processed thymus tissue-agdc) – New orphan drug approval
October 8, 2021 - The FDA announced the approval of Enzyvant’s Rethymic (allogeneic processed thymus tissue-agdc), for immune reconstitution in pediatric patients with congenital athymia.
